ES2389670T8 - Uso del PIG para el tratamiento de trastornos asociados a la transmisión sináptica disfuncional - Google Patents

Uso del PIG para el tratamiento de trastornos asociados a la transmisión sináptica disfuncional Download PDF

Info

Publication number
ES2389670T8
ES2389670T8 ES08785844T ES08785844T ES2389670T8 ES 2389670 T8 ES2389670 T8 ES 2389670T8 ES 08785844 T ES08785844 T ES 08785844T ES 08785844 T ES08785844 T ES 08785844T ES 2389670 T8 ES2389670 T8 ES 2389670T8
Authority
ES
Spain
Prior art keywords
pig
treatment
disorders associated
synaptic transmission
dysfunctional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08785844T
Other languages
English (en)
Other versions
ES2389670T3 (es
Inventor
Peter Raymond Flatt
Christian Holscher
Victor Alan Gault
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UUTech Ltd
Original Assignee
UUTech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UUTech Ltd filed Critical UUTech Ltd
Application granted granted Critical
Publication of ES2389670T3 publication Critical patent/ES2389670T3/es
Publication of ES2389670T8 publication Critical patent/ES2389670T8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES08785844T 2007-09-07 2008-09-08 Uso del PIG para el tratamiento de trastornos asociados a la transmisión sináptica desfuncional Active ES2389670T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0717388 2007-09-07
GBGB0717388.3A GB0717388D0 (en) 2007-09-07 2007-09-07 Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission
PCT/EP2008/007337 WO2009030498A2 (en) 2007-09-07 2008-09-08 Use of gip for the treatment of disorders associated with dysfunctional synaptic transmission

Publications (2)

Publication Number Publication Date
ES2389670T3 ES2389670T3 (es) 2012-10-30
ES2389670T8 true ES2389670T8 (es) 2013-02-08

Family

ID=38640380

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08785844T Active ES2389670T3 (es) 2007-09-07 2008-09-08 Uso del PIG para el tratamiento de trastornos asociados a la transmisión sináptica desfuncional

Country Status (7)

Country Link
US (1) US9062125B2 (es)
EP (1) EP2197475B1 (es)
JP (1) JP5670190B2 (es)
CA (1) CA2698766C (es)
ES (1) ES2389670T3 (es)
GB (1) GB0717388D0 (es)
WO (1) WO2009030498A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
DK2498802T3 (en) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
KR101337322B1 (ko) 2009-11-13 2013-12-06 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PL2750699T3 (pl) 2011-08-29 2015-12-31 Sanofi Aventis Deutschland Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
AU2015359376B2 (en) 2014-12-12 2021-09-09 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
GB201603510D0 (en) * 2016-02-29 2016-04-13 Univ Ulster Compositions for use in the treatment of neurological disease
JP7165495B2 (ja) * 2016-12-26 2022-11-04 花王株式会社 運動調節機能向上剤
EP3569248B1 (en) 2016-12-26 2023-12-06 Kao Corporation Gip inhibitors for improving cognitive function

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0404124D0 (en) * 2004-02-25 2004-03-31 Univ Ulster Antagonists of GIP
JP2005501058A (ja) 2001-07-31 2005-01-13 ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ Ｇｌｐ−１、ｅｘｅｎｄｉｎ−４、そのペプチド・アナログ及びその使用
JP2007523122A (ja) * 2004-02-20 2007-08-16 ノバルティス アクチエンゲゼルシャフト 神経変性障害および認知障害の処置のためのｄｐｐ−ｉｖ阻害剤
AU2006289259A1 (en) 2005-09-08 2007-03-15 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function

Also Published As

Publication number Publication date
EP2197475B1 (en) 2012-08-01
US20100204106A1 (en) 2010-08-12
JP5670190B2 (ja) 2015-02-18
ES2389670T3 (es) 2012-10-30
US9062125B2 (en) 2015-06-23
EP2197475A2 (en) 2010-06-23
CA2698766C (en) 2018-07-31
CA2698766A1 (en) 2009-03-12
JP2010538030A (ja) 2010-12-09
GB0717388D0 (en) 2007-10-17
WO2009030498A2 (en) 2009-03-12
WO2009030498A3 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
GB0717399D0 (en) Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission
GB0717388D0 (en) Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission
BRPI0816209A2 (pt) Artigos absorventes descartáveis do tipo para vestir com subsistemas de ancoramento.
CR11019A (es) 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
BRPI0807987A2 (pt) Terapia de combinação para tratamento de distúrbios imunes.
PT2323642E (pt) Utilização de edta+trometamina ou de fotoiativadores, associados a riboflavina para reticulação da córnea no tratamento de ceratocone ou de outros distúrbios ectásicos da córnea
BRPI0814405A2 (pt) Aparelho para manutenção de poço com múltiplas finalidades
BR112012013260A2 (pt) dispositivo usado para o tratamento de rinite através de iluminação bioestimulativa
BRPI1013698A2 (pt) métodos para tratamento com o uso de terapia de combinação
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
EP2442709A4 (en) ON THE BODY WORN PULSE OXIMETER
BR112012011730A2 (pt) tratamentos para distúrbios gastrointestinais
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
ES2606627T8 (es) Anticuerpos específicos anti-CD160 para el tratamiento de trastornos oculares basados en la neoangiogénesis
BRPI0911577A2 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
PT2768859T (pt) Antagonistas de il17c para o tratamento de desordens inflamatórias
FI20075738L (fi) Elimen valaiseminen
BRPI0912687A2 (pt) uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
BRPI0810091A2 (pt) Agentes fugicidas tópicos para tratar distúrbios ungueais
CL2008000110A1 (es) Uso de compuestos derivados de piranona sustituidos para el tratamiento del sindrome metabolico; y compuestos derivados de piranona sustituidos.
BRPI0910496A2 (pt) aplicação de rifalazil para tratar distúrbios colônicos.
ES1065640Y (es) Aparato para el alargamiento del pene
BR112012002267A2 (pt) compostos para o tratamento de inflamação.
BRPI0924041A2 (pt) terapias de combinação para distúrbios neoplásicos